KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Receivables (2016 - 2025)

Fulgent Genetics (FLGT) has disclosed Receivables for 11 consecutive years, with $85.9 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 21.34% to $85.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $85.9 million through Dec 2025, up 21.34% year-over-year, with the annual reading at $85.9 million for FY2025, 21.34% up from the prior year.
  • Receivables hit $85.9 million in Q4 2025 for Fulgent Genetics, up from $72.6 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $218.3 million in Q1 2021 to a low of $13000.0 in Q3 2023.
  • Historically, Receivables has averaged $84.0 million across 5 years, with a median of $73.3 million in 2025.
  • Biggest five-year swings in Receivables: crashed 99.99% in 2023 and later surged 440784.62% in 2024.
  • Year by year, Receivables stood at $139.1 million in 2021, then tumbled by 85.68% to $19.9 million in 2022, then soared by 163.19% to $52.5 million in 2023, then skyrocketed by 34.96% to $70.8 million in 2024, then increased by 21.34% to $85.9 million in 2025.
  • Business Quant data shows Receivables for FLGT at $85.9 million in Q4 2025, $72.6 million in Q3 2025, and $79.2 million in Q2 2025.